BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

260 related articles for article (PubMed ID: 32414111)

  • 1. P38 MAPK Promotes Migration and Metastatic Activity of BRAF Mutant Melanoma Cells by Inducing Degradation of PMCA4b.
    Naffa R; Vogel L; Hegedűs L; Pászty K; Tóth S; Kelemen K; Singh N; Reményi A; Kállay E; Cserepes M; Tóvári J; Grusch M; Enyedi Á
    Cells; 2020 May; 9(5):. PubMed ID: 32414111
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The plasma membrane Ca
    Hegedũs L; Garay T; Molnár E; Varga K; Bilecz Á; Török S; Padányi R; Pászty K; Wolf M; Grusch M; Kállay E; Döme B; Berger W; Hegedũs B; Enyedi A
    Int J Cancer; 2017 Jun; 140(12):2758-2770. PubMed ID: 27813079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mitogen-activated protein kinase dependency in BRAF/RAS wild-type melanoma: A rationale for combination inhibitors.
    Ming Z; Lim SY; Kefford RF; Rizos H
    Pigment Cell Melanoma Res; 2020 Mar; 33(2):345-357. PubMed ID: 31518489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Active notch protects MAPK activated melanoma cell lines from MEK inhibitor cobimetinib.
    Porcelli L; Mazzotta A; Garofoli M; Di Fonte R; Guida G; Guida M; Tommasi S; Azzariti A
    Biomed Pharmacother; 2021 Jan; 133():111006. PubMed ID: 33202284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protein phosphatase 6 activates NF-κB to confer sensitivity to MAPK pathway inhibitors in
    Zhang H; Read A; Cataisson C; Yang HH; Lee WC; Turk BE; Yuspa SH; Luo J
    Sci Signal; 2024 May; 17(836):eadd5073. PubMed ID: 38743809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RIG-I inhibits the MAPK-dependent proliferation of BRAF mutant melanoma cells via MKP-1.
    Szabo A; Fekete T; Koncz G; Kumar BV; Pazmandi K; Foldvari Z; Hegedus B; Garay T; Bacsi A; Rajnavolgyi E; Lanyi A
    Cell Signal; 2016 May; 28(5):335-347. PubMed ID: 26829212
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Positive crosstalk between ERK and p38 in melanoma stimulates migration and in vivo proliferation.
    Estrada Y; Dong J; Ossowski L
    Pigment Cell Melanoma Res; 2009 Feb; 22(1):66-76. PubMed ID: 18983537
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A C-terminal di-leucine motif controls plasma membrane expression of PMCA4b.
    Antalffy G; Pászty K; Varga K; Hegedűs L; Enyedi Á; Padányi R
    Biochim Biophys Acta; 2013 Dec; 1833(12):2561-2572. PubMed ID: 23830917
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aurora B is regulated by the mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) signaling pathway and is a valuable potential target in melanoma cells.
    Bonet C; Giuliano S; Ohanna M; Bille K; Allegra M; Lacour JP; Bahadoran P; Rocchi S; Ballotti R; Bertolotto C
    J Biol Chem; 2012 Aug; 287(35):29887-98. PubMed ID: 22767597
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of Spry1 reduces growth of BRAF
    Montico B; Colizzi F; Giurato G; Rizzo A; Salvati A; Baboci L; Benedetti D; Pivetta E; Covre A; Bo MD; Weisz A; Steffan A; Maio M; Sigalotti L; Fratta E
    Cell Death Dis; 2020 May; 11(5):392. PubMed ID: 32444628
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MED27 promotes melanoma growth by targeting AKT/MAPK and NF-κB/iNOS signaling pathways.
    Tang R; Xu X; Yang W; Yu W; Hou S; Xuan Y; Tang Z; Zhao S; Chen Y; Xiao X; Huang W; Guo W; Li M; Deng W
    Cancer Lett; 2016 Apr; 373(1):77-87. PubMed ID: 26797421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Histone Deacetylase Inhibitor Treatment Increases the Expression of the Plasma Membrane Ca
    Hegedüs L; Padányi R; Molnár J; Pászty K; Varga K; Kenessey I; Sárközy E; Wolf M; Grusch M; Hegyi Z; Homolya L; Aigner C; Garay T; Hegedüs B; Tímár J; Kállay E; Enyedi Á
    Front Oncol; 2017; 7():95. PubMed ID: 28596940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic cytotoxicity of radiation and oncolytic Lister strain vaccinia in (V600D/E)BRAF mutant melanoma depends on JNK and TNF-α signaling.
    Kyula JN; Khan AA; Mansfield D; Karapanagiotou EM; McLaughlin M; Roulstone V; Zaidi S; Pencavel T; Touchefeu Y; Seth R; Chen NG; Yu YA; Zhang Q; Melcher AA; Vile RG; Pandha HS; Ajaz M; Szalay AA; Harrington KJ
    Oncogene; 2014 Mar; 33(13):1700-12. PubMed ID: 23624923
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of p38 MAPK enhances ABT-737-induced cell death in melanoma cell lines: novel regulation of PUMA.
    Keuling AM; Andrew SE; Tron VA
    Pigment Cell Melanoma Res; 2010 Jun; 23(3):430-40. PubMed ID: 20337986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MAP kinase activity supported by BRAF (V600E) mutation rather than gene amplification is associated with ETV1 expression in melanoma brain metastases.
    Birner P; Berghoff AS; Dinhof C; Pirker C; Capper D; Schoppmann SF; Petzelbauer P; von Deimling A; Berger W; Preusser M
    Arch Dermatol Res; 2014 Dec; 306(10):873-84. PubMed ID: 25073704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination with γ-secretase inhibitor prolongs treatment efficacy of BRAF inhibitor in BRAF-mutated melanoma cells.
    Zhu G; Yi X; Haferkamp S; Hesbacher S; Li C; Goebeler M; Gao T; Houben R; Schrama D
    Cancer Lett; 2016 Jun; 376(1):43-52. PubMed ID: 27000992
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Morusin enhances the antitumor activity of MAPK pathway inhibitors in BRAF-mutant melanoma by inhibiting the feedback activation of STAT3.
    Zhao K; Dai Q; Wu J; Wei Z; Duan Y; Chen B
    Eur J Cancer; 2022 Apr; 165():58-70. PubMed ID: 35219024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting p63 Upregulation Abrogates Resistance to MAPK Inhibitors in Melanoma.
    Patel A; Garcia LF; Mannella V; Gammon L; Borg TM; Maffucci T; Scatolini M; Chiorino G; Vergani E; Rodolfo M; Maurichi A; Posch C; Matin RN; Harwood CA; Bergamaschi D
    Cancer Res; 2020 Jun; 80(12):2676-2688. PubMed ID: 32291316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Deacetylated GM3 promotes uPAR-associated membrane molecular complex to activate p38 MAPK in metastatic melanoma.
    Yan Q; Bach DQ; Gatla N; Sun P; Liu JW; Lu JY; Paller AS; Wang XQ
    Mol Cancer Res; 2013 Jun; 11(6):665-75. PubMed ID: 23525268
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Stagni C; Zamuner C; Elefanti L; Zanin T; Bianco PD; Sommariva A; Fabozzi A; Pigozzo J; Mocellin S; Montesco MC; Chiarion-Sileni V; De Nicolo A; Menin C
    Mol Cancer Ther; 2018 Jun; 17(6):1332-1340. PubMed ID: 29626128
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.